Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.35 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL27529255 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL4955812 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL354706 | 0.92 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL353690 | 0.92 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1445688 | 0.92 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5079153 | 0.90 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5706355 | 0.90 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27529254 | 0.90 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27755779 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| Fumaric Acid SCHEMBL27583993 | 0.79 | DPP4 (0.34) | DPP4DPP8DPP9DPP7GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368576-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-7368421-B2 | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis | PROBIODRUG AG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1399471-B1 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | POSPISILIK ANDREW J | 2007-09-06 | — | — | US | disclosed |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG | 2006-12-28 | — | — | US | disclosed |
| US-7109347-B2 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050171025-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2005-08-04 | — | — | US | disclosed |
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
| US-20060293248-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 4/4885DPP9 3/4885 |
| US-20050171025-A1 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | DPP4, DPP3, DNPEP | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.